focus -WSS

focus

author：knowledge 2025-09-28 20:32:53 - browse：271

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Microsoft's Peter Lee: Generative AI could help doctors be more human

hotspot

WSS

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Medicare drug price lawsuits could be good politics for Biden

Microsoft launches AI tool for clinical documentation through Epic

First over

Lack of health data on LGBTQ+ people has serious consequences

Readout Newsletter: BridgeBio, Akero, and human embryo models

Wikipedia

focus

focus

Affirmative action in medical school literally saved lives

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

How one medical school became remarkably diverse

Flu vaccine reformulation won't be easy, manufacturers warn

Virginia high school admissions case could be legal follow

Medicare bonuses could stop drug shortages under Senate plan

Supreme Court strikes down use of affirmative action

Update the Apgar Score to remove skin color

FDA approval of Sarepta Duchenne genetic therapy gives me hope

HPV vaccine, cervical cancer study delivers historic results

knowledge

Ancient Greek ideas underpin modern concepts of pregnancy

Medicare drug price negotiation continues, as pharma counteroffers

Immune cells and nerve overgrowth may explain recurring UTI pain

$1 billion proposal to grow Boston, Massachusetts biotech

CVS is on a mission to consolidate health care. Will it work?

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

explore

hotspot

focus

hotspot